2016 American Transplant Congress

June 11-15, 2016 in Boston, MA

View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z

Hand-Assisted Laparoscopic Donor Nephrectomy: Experience with Over 2400 Cases at a Single Center.

H. Li,^1,2 M. Stegall,¹ G. Chow,¹ P. Dean,¹ J. Heimbach,¹ T. Taner,¹ M. Prieto.¹
Have We Gone Too Far Defining Performance Outliers? One-Third of Kidney Transplant Programs Now Identified for Low Performance within Three Years.

J. Schold,¹ C. Miller,¹ M. Henry,² L. Buccini,¹ S. Flechner,¹ D. Goldfarb,¹ E. Poggio,¹ K. Andreonni.³
HCK Is a Potential Mediator of Renal Fibrosis.

C. Wei,¹ M. Menon,¹ L. Li,² Z. Yi,¹ K. Keung,³ C. Woytovich,¹ I. Greene,¹ W. Zhang,¹ J. He,¹ B. Murphy.¹
HCV, Acute Rejection, and the New Direct-Acting Antivirals in Deceased Donor Kidney Transplant Recipients.

C. Liao, A. Massie, S. Bae, D. Segev.
Health Disparities in Pediatric Intestinal Transplantation: Before and After the Implementation of MELD/PELD.

V. Cohran,¹ S. Mohammed,¹ J. Prozialeck,¹ A. Gaddam,¹ J. Caicedo.²
Health Insurance Trends in United States Living Kidney Donors.

J. Rodrigue,^1,2 A. Fleishman.¹
Heart and Kidney Transplants in Patients with Mechanical Circulatory Support: Who Needs a Kidney?

J. Neyer, J. Patel, M. Kittleson, D. Chang, M. Luu, T. Aintablian, E. Passano, L. Czer, F. Esmailian, J. Kobashigawa.
Heat Shock Protein 90 Inhibitor 17DMAG Is a Potential New Therapeutic Agent Against Acute Allograft Rejection.

T. Maehana,¹ T. Tanaka,¹ H. Kitamura,² N. Masumori.¹
Hematopoietic Cell Transplant and Solid Organ Transplantation: A First Report of the U.S. Experience.

M. Gupta, M. Levine, P. Abt.
Hematopoietic Progenitor Cells and Monocyte Subsets and Hepatic Decompensation in Patients Referred for Liver Transplant Evaluation.

K. Forde,¹ K. Krok,² M. Patel,¹ M. Krowka,³ M. Fallon,⁴ S. Kawut.¹
Heparanase: A New Factor Involved in the Pro-Fibrotic Renal Biological Machinery Activated by the Ischemia/Reperfusion (I/R) Injury.

G. Zaza,¹ V. Masola,¹ G. Gambaro,² M. Onisto,³ G. Bellin,¹ I. Vlodavsky,⁴ Z. Abassi,⁵ A. Lupo.¹
Hepatic Hemodynamics (HD) and Portal Flow Modulation (PM): Tactical Use in Small for Size (SFS) Live Donor Liver Transplantation (LDLT).

T. Mansour,¹ J. Pisa,¹ E. Przybyszewski,¹ J. Guarrera,¹ K. Tomoaki,¹ B. Samstein,¹ K. Halazun,² A. Griesemer,¹ J. Emond.¹
Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.

A. Nolan,¹ C. Onwudiwe,¹ A. Rangnekar,² R. Satoskar,² T. Fishbein.²
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.

A. Gonzalez, F. Forouton, A. Humar, S. Husain.
Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.

A. Morales,¹ M. Singla,² H. Greenwald,¹ S. Robertazzi,¹ C. Rodigas,¹ V. Washington,¹ R. Satoskar,¹ C. Smith.¹
Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival.

J. Kim,¹ K.-W. Lee,² G.-W. Song,³ B.-H. Jung,³ H. Lee,⁴ N.-J. Yi,² C. Kwon,¹ S. Hwang,³ K.-S. Suh,² J.-W. Joh,¹ S.-K. Lee,¹ S.-G. Lee.³
Hepatitis E Virus (HEV) Infection Among Kidney Transplant Patients in a Northeast US Center.

M. Lim,¹ S. Kamili,² T. Greene,² A. Tejada-Strop,² J. Drobeniuc,² M. Vanderveen,¹ R. Bloom.¹
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.

S. Prenner, L. VanWagner, L. Kulik.
Here Comes the Sun: Industry's Payments to Transplant Physicians.

R. Ahmed,¹ E. Chow,² S. Bae,² A. Massie,² E. King,² B. Orandi,² J. Lopez,² B. Lonze,² D. Segev.²
Heterologous Persistent and Latent Viral Infections Do Not Impact Graft Survival.

J. Espinosa,^1,2 M. McRae,¹ J. Wang,¹ A. Kirk.¹
Hif-1α Stabilization in the Recipient Accelerates Cardiac Allograft Rejection.

Z. Ilyas, M. DeBerge, S. Dehn, J.-J. Wang, Z. Zhang, E. Thorp, M. Ansari.
High Concentrations of CXCL9 and CXCL10 Chemokines but Not CXCL8 (IL-8), IL-6, TNF-a or IFN-g in Biopsy Tissue Are Associated with Pathological Staging of Rejection After Kidney Transplantation.

C. Falk,¹ C. Neudörfl,¹ K. Daemen,¹ J. Keil,¹ F. Lehner,² H. Haller,³ J. Schmitz,⁴ C. Blume,⁵ J.-H. Bräsen.⁴
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.

M. Charlton,¹ E. Yoshida,² M. Bouliere,³ S. Flamm,⁴ A. Muir,⁵ M. Fried,⁶ N. Terrault,⁷ S. Arterburn,⁸ C. Yun,⁸ P. Pang,⁸ A. Osinusi,⁸ J. Spellman,⁸ M. Natha,⁸ D. Brainard,⁸ J. McHutchison,⁸ M. Manns,⁹ N. Afdhal.¹⁰
High Incidence of Herpes Zoster After Kidney, Liver, Heart and Lung Transplantation.

N. van Besouw, S. Roest, D. Bovée, H. Metselaar, R. Hoek, J. van Weezel, A. van der Eijk, W. Weimar, O. Manintveld, M. Kho.
High KDPI Is a Predictor of Acute Rejection in Delayed Graft Function.

B. Muth,¹ J. Turk,¹ S. Parajuli,¹ D. Mandelbrot,¹ M. Mohamed,¹ R. Redfield,² D. Kaufman,² A. Djamali.^1,2
High KDPI Kidneys (>85%) Do Not Adversely Affect HRQOL After Kidney Transplantation.

R. Forbes, I. Feurer, D. LaNeve, C. Gamble, D. Shaffer.
High PD-L1/CD86 MFI Ratio and IL-10 Secretion Characterize Maturation-Resistant Human Regulatory Dendritic Cells (DCregs) Generated for Clinical Testing in Transplantation.

A. Zahorchak,¹ L. Butterfield,^2,3 C. Macedo,¹ D. Hamm,⁴ D. Metes,^1,3 A. Thomson.^1,3
High Resolution Detection of Human Pancreatic Islet Damage During and After Isolation Procedure Using MicroRNAs.

S. Prathab Balaji,¹ M. Kanak,² G. Yoshimatsu,¹ C. Chang,¹ M. Levy,² M. Lawrence,¹ P. Kim,³ N. Onaca,³ B. Naziruddin.³
High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.

O. Rissling, S. Brakemeier, L. Lehner, F. Halleck, O. Staeck, D. Schmidt, K. Budde.
High-Risk Age Window for Graft Loss in Pediatric Lung and Heart Transplant Recipients.

B. Orandi, X. Luo, K. Van Arendonk, R. Higgins, D. Segev.
High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients.

D. Berglund,¹ D. Schladt,² K. Sanghavi,¹ W. Guan,¹ B. Wu,¹ C. Dorr,³ R. Remmel,¹ R. Mannon,⁴ A. Matas,¹ W. Oetting,¹ A. Israni,³ P. Jacobson,¹ DeKAF Genomics Investigators.
Higher Functional Capacity Prior to Kidney Transplant Confers Lower Risk of New Onset Diabetes After Transplantation.

I. Qaqish, S. Behmen, R. Heilman, H. Khamash, J. Huskey, S. Nair, H. Chakkera.
Higher Pre-Transplant HDL Levels Are Associated with Decreased Acute Rejection Following Kidney Transplant.

J. Hagopian,¹ D. Brennan,² K. Lentine,³ T. Horwedel.¹
Higher Pre-Transplant Triglyceride Levels Are Associated with Increased Acute Cellular Rejection Risk Following Kidney Transplant.

J. Hagopian,¹ D. Brennan,² K. Lentine,³ T. Horwedel.¹
Highly Sensitized Patients Transplanted via the Eurotransplant Acceptable Mismatch Program Have Excellent Long-Term Graft Survival.

S. Heidt, M. Witvliet, G. Haasnoot, F. Claas.
Histone Deacetylase-2 Gene Deletion in Mice Mitigates Liver Ischemia/Reperfusion Injury.

D. Murken,¹ D. Aufhauser Jr,¹ Z. Wang,² G. Ge,² W. Hancock,^2,3 M. Levine.^1,4
HLA Antibody Clonality and Epitopes Dictate Complement Activation.

K. Thomas,¹ N. Valenzuela,¹ A. Mulder,² E. Reed.¹
HLA Antibody in Transplant Recipients During Transition from Paediatrics.

S. Kaki,¹ A. Lunn,² J. Goodwin,³ T. Key,³ W. McKane.¹
HLA Class II and BK Virus Reactivation in Renal Transplant Recipients.

P. Shah,¹ K. Anderson,² M. Aubrey,² C. Roark,² B. Freed,² A. Wiseman.¹
HLA Identical or Haploidentical Combined Kidney and Bone Marrow Transplantation for Multiple Myeloma with End-Stage Renal Failure.

T. Kawai,¹ Y.-B. Chen,¹ M. Sykes,² C. Benedict,¹ N. Tolkoff-Rubin,¹ B. Day,¹ S. McAfee,¹ K. Ballen, S. David,¹ T. Spitzer.¹
HLA Identical Renal Transplant Tolerance Using Donor Hematopoietic Stems Cells (DHSC): Role of Immunoregulation.

J. Leventhal,¹ J. Mathew,¹ D. Salomon,² S. Kurian,² J. Friedewald,¹ L. Gallon,¹ X. Huang,¹ A. Tambur,¹ Y. Kanwar,¹ J. Charette,¹ M. Abecassis,¹ J. Miller.¹
HO-1/SIRT1/p53 Axis Regulates Macrophage Activation and Attenuates Liver Ischemia-Reperfusion Injury in Mice.

K. Nakamura,¹ M. Zhang,² B. Ke,¹ S. Kageyama,¹ R. Busuttil,¹ J. Araujo,² J. Kupiec-Weglinski.¹
Hospital Readmissions Following Discharge After Liver Transplantation (LT).

E. Minja, S. Chinnakotla, K. Yadav, A. Pugalenthi, O. Serrano, R. Kandaswamy, W. Payne, T. Pruett, V. Kirchner.
Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.

B. Orandi, E. King, X. Luo, S. Bae, B. Lonze, R. Montgomery, D. Segev.
Hospital Readmissions in the First Year Post Transplant Over a 12-Year Span at a Single Center.

C. Avila, I. James, G. Phillips, A. El-Hinnawi, A. Rajab, R. Pelletier, M. Henry, G. Bumgardner.
Hospitalization and Living Donor Kidney Transplantation Among Waitlisted End Stage Renal Disease Patients in the US.

K. Newman,^1,2 A. Adams,² S. Pastan,² R. Lynch,² R. Zhang,¹ R. Patzer.^1,2
Hospitalizations for Cardiovascular Disease After Kidney Transplantation: The Role of Facility Characteristics on Outcomes and Costs.

A. Mathur, Y.-H. Chang, D. Steidley, N. Katariya, A. Singer, W. Hewitt, K. Reddy, N. Wasif, D. Etzioni, A. Moss.
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Epidemiology, Outcomes, and Costs.

A. Mathur, Y.-H. Chang, D. Steidley, N. Khurmi, N. Katariya, A. Singer, W. Hewitt, K. Reddy, A. Moss.
Hospitalizations, Survival, and Complications: 1-Year Outcomes for Elderly Lung Transplant Recipients.

N. Casciello, A. Fuentes, J. Krisl, N. Sinha, T. Kaleekal.
How Did the New Kidney and Pancreas Allocation Systems Effect Pancreas Utilization in the First Six-Months?

R. Carrico,¹ J. Fridell,² J. Odorico,³ Z. Stewart.⁴
How Small Is Too Small: A Comparison of Access and Survival by Weight in Pediatric Liver Transplant Recipients.

E. Steen, R. Cotton, A. Rana.
How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.

S. Papachristos, A. John Velvet, A. Summers, A. Tavakoli, R. Dhanda, R. Pararajasingam, B. Forgacs.
Human and Mouse Treg Use Lymphotoxin for Migration Across Lymphatic Endothelium.

C. Brinkman,¹ K. Hippen,² B. Blazar,² J. Bromberg.¹
Human B Cell Cytokines Predict Renal Allograft Rejection and Early Transplant Outcomes.

A. Cherukuri, R. Mehta, S. Ogunde, S. Hariharan, D. Rothstein.
Human Epineural Allograft Conduits Supported with Mesenchymal Stem Cells Enhance Peripheral Nerve Regeneration: A Preliminary Report.

M. Siemionow, M. Strojny, W. Malewski, J. Cwykiel, M. Cyran.
Human Leukocyte Antigen (HLA) Mismatch Impact on Lung transplants outcomes.

G. Chery,¹ L. Snyder,¹ M. Durheim,¹ S. Palmer,¹ M. Neely.²
Human Leukocyte Antigen-E Expression on Porcine GalTKO.hCD46 Cells Improves Ex-Vivo Xenograft Survival and Attenuates Injury.

C. Laird,¹ N. Kubicki,¹ L. Burdorf,¹ T. Zhang,¹ X. Chang,¹ G. Braileanu,¹ C. Phelps,² D. Ayares,² A. Azimzadeh,¹ R. Pierson.¹
Human MicroRNA Responses Are Predictive of CMV Reactivation Following Solid Organ Transplant.

S. Han,¹ D. Kumar,¹ V. Ferreira,¹ S. Husain,¹ N. Mueller,² A. Humar,¹ M. Mian,¹ P. Ashton.¹
Human Multipotent Mesenchymal Stromal Cells Improve Survival and Function of Pancreatic Islets by Cell-to-Cell Contact.

E. Montanari,¹ R. Meier,² D. Bosco,¹ R. Mahou,³ P. Morel,² J. Seebach,⁴ C. Wandrey,³ C. Gonelle-Gispert,¹ L. Bühler.²
Human PDL1⁺ SLA-DR^–Swine Vascular Endothelial Cells Suppress Pig-Human PBMC Xeno-MLR(Mixed Lymphocyte Reaction) by Inducing Human Regulatory IL-10⁺Tr1(Type 1 Regulatory T Cells) Subset for Suppression of Xenogeneic Reactions.

Q. Shao, Q. Diag.
Hydrogen Sulfide Supplementation Helps Mitigate Effects of Ischemia Reperfusion Injury in a Murine Model of Donation After Cardiac Death Renal Transplantation.

J. Grewal,¹ I. Lobb,¹ M. Saha,² J. Jiang,² A. Haig,¹ A. Sener.^1,2
Hydrogen Sulfide Treatment Mitigates Donor Tissue Necrosis During Prolonged Cold Storage and Improves Survival Following Allogeneic Renal Transplantation.

I. Lobb,^1,3 W. Liu,² J. Jiang,³ D. Lian,³ A. Sener.^1,3,4
Hydrogen Sulphide Is an Important Regulator of Erythropoietin Synthesis in Patients with Anemia of Chronic Kidney Disease.

J. Leigh,¹ P. Shao,¹ M. Saha,¹ I. Lobb,¹ A. Pasch,⁵ H. van Goor,⁴ M. Feelisch,² R. Wang,³ A. Sener.¹
Hyponatremia in Early Post Lung Transplantation Predicts Patient and Hospital Outcomes.

E. Tantisattamo,¹ A. Chokechanachaisakul,² O. Traitanon,³ A. Shetty,² B. Ho,² J. Friedewald,² S. Bhorade,² A. Haynes,² A. Nieland,² L. Gallon.²
Hypothermic Machine Perfusion Ameliorates Vasospasm and Edema of Podocytes and Renal Tubular Epithelial Cells Through Upregulating Expression of Krüppel-Like Factors 2.

Z. Zhong,¹ D. Ko,² Y. Wang,¹ Q. Ye.¹
Hypothermic Machine Perfusion Is Also Beneficial for Deceased Donor Kidneys When Cold Ischemic Time Is Short and a Short Cold Ischemic Time Is Also Beneficial When Kidneys Are Machine Perfused.

J. Kox,¹ C. Moers,² D. Monbaliu,³ A. Strelniece,⁴ J.-W. Treckmann,⁵ I. Jochmans,³ H. Leuvenink,² L. van Heurn,¹ J. Pirenne,³ A. Paul,⁵ R. Ploeg.^2,6

Jump to: View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z